Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Research Article

Identification, Characterization, and the Determination of Process-related Impurities in Minodronic Acid Bulk Drug

Author(s): Shi Anan, Zou Qiaogen* and Gao Pan

Volume 18, Issue 3, 2022

Published on: 27 July, 2021

Page: [325 - 335] Pages: 11

DOI: 10.2174/1573412917666210604160621

Abstract

Background: Minodronic acid (MA) is a third-generation nitrogen-containing heterocyclic bisphosphonate used to treat osteoporosis. In the process of starting materials research and preparation, the key intermediate impurities and degradation impurities have a great impact on the quality control of the drug.

Objectives: A sensitive, reliable, high-performance liquid chromatography (HPLC) method was developed and validated for the quantitative determination of MA and its related impurities (a total of 6 compounds, including 2 new impurities).

Methods: The separation was achieved on an InertSustain ODS-4 C18 (250 mm × 4.6 mm, 5 μm) column using the mixture of 0.01 mol/L sodium pyrophosphate and 1 mmol tetrabutylammonium phosphate (the mobile phase pH was adjusted to 7.80 by phosphonic acid).

Results: The quantitative analytical method was fully validated with respect to linearity (r > 0.999), sensitivity (limit of detection < 35 ng/mL), precision, accuracy (the recovery was between 98.7% and 104.2%), and robustness. Six process-related impurities in Minodronic Acid (MA) bulk drug were determined by high-performance liquid chromatography (HPLC). Furthermore, except for two starting materials, other four impurities were identified and characterized as 2-(imidazo[1,2-a] pyridin-3-yl) ethyl acetate (Imp-C), 2-(imidazo [1,2-a] pyridin- 3- yl)acetic acid (Imp-D), 3-(2-hydroxy-2,2- diphosphonoethyl)-4H-imidazo [1,2-a] pyridine -4- oxide (Imp-E) and 2,5- Dihydroxy- 3,6-bis(imidazo[1,2-a] pyridine-3-yl methyl) -2,5-dioxo- 1,4,2,5- dioxoDiphosphonium-3,6-diyl) bisphosphonic acid (Imp-F) using liquid chromatograph- mass spectrometer (LC-MS), MS/MS, Infrared Radiation and Nuclear Magnetic Resonance spectroscopy (1H-NMR and 13C-NMR). To the best of our knowledge, two of them (Imp- E and Imp-F) are new compounds and have not been reported previously.

Conclusion: The HPLC method was developed and optimized, which could be applied for quantitative detection of the impurities, and further quality evaluation of MA.

Keywords: Minodronic acid, impurities, structural elucidation, NMR, quantification, high-performance liquid chromatography.

« Previous Next »
Graphical Abstract

[1]
Imai A, Matsunami K, Ichigo S, Takagi H. Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: A retrospective pilot study. Gynecol Endocrinol 2016; 32(3): 250-2.
[http://dx.doi.org/10.3109/09513590.2015.1112783] [PMID: 26503621]
[2]
Hasegawa E, Ito S, Takai C, et al. The efficacy of minodronate in the treatment of glucocorticoid-induced osteoporosis. Intern Med 2018; 57(15): 2169-78.
[http://dx.doi.org/10.2169/internalmedicine.9885-17] [PMID: 29607978]
[3]
Mashiba T, Saito M, Yamagami Y, Tanaka M, Iwata K, Yamamoto T. Effects of suppressed bone remodeling by minodronic acid and alendronate on bone mass, microdamage accumulation, collagen crosslinks and bone mechanical properties in the lumbar vertebra of ovariectomized cynomolgus monkeys. Bone 2017; 97: 184-91.
[http://dx.doi.org/10.1016/j.bone.2017.01.008] [PMID: 28082077]
[4]
Hilton JF, Clemons M, Pond G, et al. Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer. J Bone Oncol 2017; 10: 6-13.
[http://dx.doi.org/10.1016/j.jbo.2017.11.001] [PMID: 29204337]
[5]
Tanishima S, Morio Y. A review of minodronic acid hydrate for the treatment of osteoporosis. Clin Interv Aging 2013; 8: 185-9.
[http://dx.doi.org/10.2147/CIA.S23927] [PMID: 23440003]
[6]
Tanaka M, Matsugaki A, Ishimoto T, Nakano T. Evaluation of crystallographic orientation of biological apatite in vertebral cortical bone in ovariectomized cynomolgus monkeys treated with minodronic acid and alendronate. J Bone Miner Metab 2016; 34(2): 234-41.
[http://dx.doi.org/10.1007/s00774-015-0658-2] [PMID: 25837430]
[7]
Wei-Jie S, Yue-Ying Z, Li-Qiang W, et al. Determination of the content and related substances of minodronic acid by HPLC. Chin J N Drugs 2018; 27: 1932-8.
[8]
Zhang H, Sun L, Zou L, et al. Identification, characterization and HPLC quantification of process-related impurities in Trelagliptin succinate bulk drug: Six identified as new compounds. J Pharm Biomed Anal 2016; 128: 18-27.
[http://dx.doi.org/10.1016/j.jpba.2016.04.041] [PMID: 27209451]
[9]
Abdelrahman MM, Abdelwahab NS. Analysis of carbamazepine, oxcarbazepine, their impurities, and non-labeled interfering substances by stability-indicating uplc/ms/ms method: Studying the method’s greenness profile. Chro 2018; 81: 1503-17.
[http://dx.doi.org/10.1007/s10337-018-3623-0]
[10]
Husain SRN. Monitoring of process impurities in drugs. Chro Libr 1998; 60: 833-88.
[11]
Zhou Y, He X, Li H, et al. Pharmacokinetics and tolerability of minodronic acid tablets in healthy Chinese subjects and food and age effects on the pharmacokinetics. Clin Ther 2015; 37(4): 869-76.
[http://dx.doi.org/10.1016/j.clinthera.2015.01.015] [PMID: 25748293]
[12]
van den Elzen MT, van Os-Medendorp H, Röckmann-Helmbach H, et al. Allergenicity and safety of recombinant human C1 esterase inhibitor in patients with allergy to rabbit or cow’s milk. J Allergy Clin Immunol 2016; 138(2): 476-481.e1.
[http://dx.doi.org/10.1016/j.jaci.2016.04.019] [PMID: 27321437]
[13]
Beyer T, Diehl B, Randel G, et al. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal 2008; 48(1): 13-9.
[http://dx.doi.org/10.1016/j.jpba.2008.06.014] [PMID: 18678460]
[14]
Liu KKC, Sakya SM, O’Donnell CJ, Flick AC, Li J. Synthetic approaches to the 2009 new drugs. Bioorg Med Chem 2011; 19(3): 1136-54.
[http://dx.doi.org/10.1016/j.bmc.2010.12.038] [PMID: 21256756]
[15]
Q2A, hamonised tripartite guideline, validation of analytical procedures: Step 4 version International conference on harmonization Geneva 2005.
[16]
Jin-bo C, Shi-ming Z, Zhen-fu L, et al. Improvement of synthetic process of disodium minophosphonate. W Chin J Phar 2012; 27: 615-7.
[17]
Ito M, Sone T, Fukunaga M. Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis. J Bone Miner Metab 2010; 28(3): 334-41.
[http://dx.doi.org/10.1007/s00774-009-0138-7] [PMID: 19937358]
[18]
Zaman B, Hassan W. Development of stability indicating hplc–uv method for determination of daclatasvir and characterization of forced degradation products. Chro 2018; 81(5): 785-97.
[http://dx.doi.org/10.1007/s10337-018-3503-7]
[19]
Yuan JY, Zhang D, Hu XN, et al. Synthesis and characterization of four process impurities in pazopanib. Pharmazie 2018; 73(9): 494-7.
[PMID: 30223930]
[20]
He Z, He Z, Wei C, Gao H, Li Y, Che D. Identification, synthesis and characterization of new impurities in tenofovir. Pharmazie 2015; 70(5): 283-8.
[PMID: 26062294]

Rights & Permissions Print Cite
Article Metrics
15
1
© 2024 Bentham Science Publishers | Privacy Policy